<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

• Hauptverfasser: Andrés Barba (Verfasst von), Laura López-Vilaró (Verfasst von), Malena Ferre (Verfasst von), Margarita Majem (Verfasst von), Sergio Martinez-Recio (Verfasst von), Olga Bell (Verfasst von), María J. Arranz (Verfasst von), Juliana Salazar (Verfasst von), Ivana Sullivan (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2024-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Standard first-line chemotherapy in small cell lung cancer (SCLC) is based on the platinum plus etoposide combination. Despite a high objective response rate, responses are not durable and chemotherapy-induced toxicity may compromise treatment. Genetic variants in genes involved in the DNA-repair pa...